Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

How Zymeworks aims to take on Roche’s $10B HER2 franchise

Zymeworks is taking on Roche’s $10B HER2 franchise using bispecifics in a ‘displace and expand’ strategy

Stephen Hansen, Associate Editor
July 11, 2019 10:00 PM UTC

Zymeworks is going head to head with one of the biggest commercial cancer franchises -- Roche’s Herceptin trastuzumab and Perjeta pertuzumab -- as it pursues clinical proof-of-concept for its protein engineering platform.

Pivotal readouts in 2022 from its lead bispecific program, along with additional data from the biotech’s first ADC, will provide the first glimpse of whether Zymeworks Inc.'s technologies can generate best-in-class molecules that outperform combinations of individual mAbs. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Roche

Zymeworks Inc.